Clinical Trial Update: Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study [Phase 4]

View source ↗

Summary

This Phase 4 study evaluated rivaroxaban for anticoagulation around cardioversion in patients with atrial fibrillation and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Cook County Health | Conditions: Atrial Fibrillation, Stroke | Phase 4 | Status: COMPLETED